Poster presentation at Gordon Research Conference on Transglutaminase in human disease processes
10.07.2016 - 15.07.2016 in Girona, Spain

"DD-XLink-mab" directed against the crosslinked fibrin neoepitope

Ricarda Ziegler, Andreas Heil, Christiane Pelzer, Michael Sommer, Robert Jähnig, Christian Büchold, Martin Hils, Ralf Pasternack
Zedira GmbH, Rösslerstrasse 83, 64293 Darmstadt, Germany

Since decades, coagulation factor XIII (FXIII) is considered as a scientific qualified target for the development of novel anticoagulants [1-3]. Inhibiting FXIII may lower the current bleeding risk in anticoagulation therapy since neither the thrombin level nor the platelet activation is affected.
Zedira develops small molecule inhibitors to modulate FXIII activity by structureassisted drug design [4]. To assess the efficacy in blood, we aimed to generate a monoclonal antibody directed against the isopeptide bond (“crosslink”) within fibrin as preferred biomarker. After proteolytic activation by thrombin, FXIIIa modifies the soft fibrin clot and thereby introducing covalent bonds. First, crosslinking between abutting γ-chains of fibrin is catalyzed and subsequently α2-antiplasmin is incorporated to further increase the resistance against fibrinolysis (figure 1A). Plasmin catalyses the retarded clot dissolution and the release of crosslinked fibrin degradation products (xFDPs / D-dimer). In case of blocking FXIIIa only a soft clot is formed which may be rapidly hydrolyzed yielding non-crosslinked fibrin degradation products (FDPs, figure 1B).
SDS-PAGE of those degradation products reveals that the protein pattern differs remarkably under reduced and non-reduced conditions as shown in figure 1C.
Monoclonal “D-dimer” antibodies (e.g. DD-3B6/22) are commercially available and are used in In Vitro Diagnostics (IVD) to exclude thromboembolic events. However, these monoclonals do not detect the crosslink itself but address a portion of polypeptides within the D-domain after plasmin degradation that are conformationally reactive [7]. This hinders for example standardization and comparison of data obtained by different assays [8]. Therefore, we developed "DD-XLink-mab“ (A076) which directly recognizes the crosslinked fibrin neoepitope.

Synthesis of the antigen and immunization
A peptide sequence derived from human γ-fibrinogen containing Q398/Q399 and K406 was synthesized by standard solid-phase peptide chemistry. The purified peptide was subsequently cross-linked using thrombin activated FXIII (FXIIIa, Zedira, T070). Mass spectrometry confirmed the formation of iso-peptide bonds. After conjugation to Keyhole Limpet Hemocyanin (KLH), the conjugate was used for immunization of three mice. Serum of one mouse showed mild reactivity against crosslinked fibrin degradation products (xFDPs), which was used as read out both in ELISA and in Western-blotting. Spleen-derived B-cells from this mouse were fused to myeloma cells yielding hybridoma cell lines. Separation and further screening lead to a single clone producing a monoclonal antibody (named A076) with a substantial reactivity against xFDPs in ELISA.

Characterization of the monoclonal antibody (mAb)
The specific requirement for the monoclonal antibody (mAb) is to discriminate between crosslinked and non-crosslinked fibrin. In addition, selectivity against fibrinogen and other blood components is indispensable.
Production of xFDPs and FDPs: coagulation was simulated in vitro by adding thrombin to a mixture of human fibrinogen (Zedira, F004) and rhFXIII (Zedira, T027) in physiological concentrations either in the presence or absence of ZED3118, a direct-acting FXIIIa inhibitor. The insoluble fibrin clots were subsequently degraded by rhPlasmin (Zedira, P012) and the soluble proteins were separated by gel filtration chromatography. These protein preparations are used for ELISA and SDS-PAGE with subsequent Western-blotting.
Immune-staining of xFDPs and FDPs by commercially available “D-dimer” monoclonal antibody (DD-3B6/22) is shown in figure 2. The pattern reveals that in contrast to our novel DD-XLink-mab“ A046 both xFDPs and FDPs are recognized under non-reducing conditions only, in accordance with the literature [7]. Westernblotting using novel "DD-XLink-mab“ (A076) indicates specificity for the cross-linked fibrin both under non-reducing and reducing conditions (figure 2b). The antibody shows no reactivity against fibrinogen or other plasma proteins.

fibrin crosslinking

Figure 1: A) Upon clot formation, activated factor FXIII (FXIIIa) modifies the soft fibrin clot by rapidly crosslinking γ-chains of fibrin and incorporation of α2-antiplasmin. Thus FXIIIa increases clot stiffness and resistance against fibrinolysis. Plasmin catalyses the retarded release of crosslinked fibrin degradation products (xFDPs) and the characteristic “D-dimers”.

Figure 1: B) Inhibition of FXIIIa leads to the fibrin fiber assembly without covalent modification. The so called “soft clot” is highly susceptible for fibrinolysis leading to fibrin degradation products (FDPs).
D-Dimer PAGE
Figure 1: C) Coomassie stained SDS-PAGE of fibrinogen, crosslinked fibrin degradation products (xFDPs) and non-crosslinked fibrin degradation products (FDPs) under non-reduced and reduced conditions. The most characteristic bands are referenced.
D-Dimer Blot
DD-XLink-mab A076 Blot

Figure 2: Western-blotting using A) “D-dimer” (DD-3B6, Zedira A046) and B) our novel DD-XLink-mab“ (Zedira, A076). Fibrinogen, crosslinked fibrin degradation products (xFDPs) and non-crosslinked fibrin degradation products (FDPs) under non-reduced and reduced conditions have been used according to Figure 1C. The most characteristic bands are referenced according to [6].

We developed and characterized “DD-XLink-mab“ (A076) directed against the major crosslink within the γ-chains of human fibrin. The recognized neoepitope is clearly distinct from the one recognized by commercial “D-dimer” antibodies used in IVD for exclusion of thrombotic events. We expect that the novel monoclonal antibody will be a valuable tool for basic hemostaseology and transglutaminase research. Further, the evaluation in IVD, for clot imaging, and especially in course of our FXIII drug development program is ongoing.

[1] Lorand L. & Jacobsen A., Nature, 1962;
[2] Shebuski R.J. et al., Blood, 1990;
[3] Lorand L., J. Throm. Haemost., 2005;
[4] Stieler M. et al., Angew. Chem. Int. Ed., 2013;
[5] Wylie F.G. & Walsh T.P., Blood Coagul Fibrinolysis, 1997;
[6] Pizzo S.V. et al., J. Biol. Chem., 1972;
[7] Devine D.V. & Greenberg C.S., Am J Cin Pathol, 1988;
[8] Adam S.S. et al., Blood, 2009


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA